| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-09-07 17:13:01 UTC |
|---|
| Updated at | 2022-09-07 17:13:01 UTC |
|---|
| NP-MRD ID | NP0253363 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | epirubicin |
|---|
| Description | Epirubicin, also known as 4'-epiadriamycin or farmorubicin, belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage. Epirubicin is a drug which is used for use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Epirubicin is a very strong basic compound (based on its pKa). Epirubicin is a potentially toxic compound. epirubicin is found in Streptomyces venezuelae. epirubicin was first documented in 2001 (PMID: 11432615). An anthracycline that is the 4'-epi-isomer of doxorubicin (PMID: 15821120) (PMID: 16005104) (PMID: 17604344) (PMID: 18838875). |
|---|
| Structure | COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 4'-Epiadriamycin | ChEBI | | Epiadriamycin | ChEBI | | Epirubicina | ChEBI | | Epirubicine | ChEBI | | Epirubicinum | ChEBI | | Pidorubicina | ChEBI | | Pidorubicine | ChEBI | | Pidorubicinum | ChEBI | | Farmorubicin | Kegg | | Ellence | HMDB | | Farmorubicine | HMDB | | IMI 28 | HMDB | | IMI28 | HMDB | | Lemery brand OF epirubicin hydrochloride | HMDB | | Pharmorubicin | HMDB | | Cell pharm brand OF epirubicin | HMDB | | 4' Epi adriamycin | HMDB | | 4' Epi DXR | HMDB | | 4' Epiadriamycin | HMDB | | 4' Epidoxorubicin | HMDB | | 4'-Epi-adriamycin | HMDB | | 4'-Epi-doxorubicin | HMDB | | EPIcell | HMDB | | Farmorubicina | HMDB | | 4'-Epidoxorubicin | HMDB | | EPI cell | HMDB | | Hydrochloride, epirubicin | HMDB | | IMI-28 | HMDB | | 4' Epi doxorubicin | HMDB | | 4'-Epi-DXR | HMDB | | EPI-cell | HMDB | | Epilem | HMDB | | Epirubicin hydrochloride | HMDB | | Kenfarma brand OF epirubicin hydrochloride | HMDB | | Pfizer brand OF epirubicin hydrochloride | HMDB | | Epirubicin | ChEBI |
|
|---|
| Chemical Formula | C27H29NO11 |
|---|
| Average Mass | 543.5193 Da |
|---|
| Monoisotopic Mass | 543.17406 Da |
|---|
| IUPAC Name | (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione |
|---|
| Traditional Name | epirubicin |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O |
|---|
| InChI Identifier | InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1 |
|---|
| InChI Key | AOJJSUZBOXZQNB-VTZDEGQISA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Phenylpropanoids and polyketides |
|---|
| Class | Anthracyclines |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Anthracyclines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Anthracycline
- Anthracyclinone-skeleton
- Aminoglycoside core
- Tetracenequinone
- 9,10-anthraquinone
- 1,4-anthraquinone
- Anthracene
- Hexose monosaccharide
- Glycosyl compound
- O-glycosyl compound
- Tetralin
- Aryl ketone
- Anisole
- Amino saccharide
- Alkyl aryl ether
- Benzenoid
- Oxane
- Monosaccharide
- Vinylogous acid
- Tertiary alcohol
- Alpha-hydroxy ketone
- Secondary alcohol
- 1,2-aminoalcohol
- Ketone
- Acetal
- Organoheterocyclic compound
- Polyol
- Ether
- Oxacycle
- Alcohol
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organic nitrogen compound
- Amine
- Primary amine
- Primary alcohol
- Primary aliphatic amine
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Razis ED, Fountzilas G: Paclitaxel: epirubicin in metastatic breast cancer--a review. Ann Oncol. 2001 May;12(5):593-8. doi: 10.1023/a:1011108807105. [PubMed:11432615 ]
- Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo KS, Doval DC, Ermisch S, Roychowdhury D, Miller MA, von Minckwitz G: First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005 Jun;16(6):899-908. doi: 10.1093/annonc/mdi181. Epub 2005 Apr 8. [PubMed:15821120 ]
- Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P, Lecomte J, Collon T, Mommen P, Sculier JP: A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer. 2005 Oct;50(1):75-82. doi: 10.1016/j.lungcan.2005.05.007. [PubMed:16005104 ]
- Iwakiri T, Okumura M, Hidaka M, Kumagai Y, Ichihara E, Kawano Y, Arimori K: Inhibition of carrier-mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes. J Appl Toxicol. 2008 Apr;28(3):329-36. doi: 10.1002/jat.1283. [PubMed:17604344 ]
- Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD: A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am J Clin Oncol. 2008 Oct;31(5):413-6. doi: 10.1097/COC.0b013e318168ef2a. [PubMed:18838875 ]
- LOTUS database [Link]
|
|---|